---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-114456"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T09:21:40.177595+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma Reports Phase 3 BROADWAY and TANDEM Data Published in NEJM and Lancet

## Summary
- BROADWAY trial showed 33% LDL-C reduction (p<0.0001) vs placebo and a 21% relative reduction in MACE (HR=0.79).
- TANDEM trial fixed-dose combination of obicetrapib and ezetimibe achieved 48.6% LDL-C reduction vs placebo (p<0.001).
- Pooled Lp(a) analysis across three Phase 3 trials showed a median placebo-adjusted reduction of 45% at 12 weeks.
- Obicetrapib plus moderate statins lowered LDL-C by 69% (atorvastatin 20 mg) and 64% (rosuvastatin 10 mg) in a Phase 2 trial.
- Phase 2 data showed synergy in plaque prevention: combination of obicetrapib and ezetimibe reduced plaque formation by 98% vs 78% independently.

## SEC filing metadata
- accession: 0001193125-25-114456
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312525114456/0001193125-25-114456-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312525114456/d905689d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-114456
- JSON: https://secwatch.observer/filing/0001193125-25-114456.json
- Plain text: https://secwatch.observer/filing/0001193125-25-114456.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.